- ►diabetesjournals.org DD De León, S Deng, R Madani, RS Ahima, DJ … - Diabetes, 2003 - Am Diabetes Assoc A reduction in β-cell mass is an important causative factor in type 1 and type
2 diabetes. Glucagon-like peptide-1 (GLP-1) and the long-acting agonist exendin
4 (Ex-4) expand β-cell mass by stimulating neogenesis and proliferation. ... Cited by 105 - Related articles - BL Direct - All 6 versions
- ►glucagon.com [PDF] Z Ling, D Wu, Y Zambre, D Flamez, DJ Drucker … - Virchows Archiv, 2001 - Springer Abstract Glucagon-like peptide 1 (GLP-1) amplifies glucose-induced insulin
release in vivo and in vitro. Ac- tivation of GLP-1 receptor (GLP-1R) signaling
leads to differentiation of exocrine cells towards a β-cell pheno- type in ... Cited by 50 - Related articles - BL Direct - All 5 versions
Q Wang, P Brubaker - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 ameliorates the symptoms of diabetes
through stimulation of insu- lin secretion and enhancement of beta-cell mass. We
have therefore investigated the effects of glucagon- like peptide-1 on the ... Cited by 137 - Related articles - BL Direct - All 4 versions
- ►glucagon.com [PDF] Y Li, T Hansotia, B Yusta, F Ris, PA Halban, … - Journal of Biological Chemistry, 2003 - ASBMB Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments β
cell mass via activation of β cell proliferation and islet neogenesis. We
examined whether GLP-1 receptor signaling modifies the cellular ... Cited by 252 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org C Tourrel, D Bailbé, MJ Meile, M Kergoat, B … - Diabetes, 2001 - Am Diabetes Assoc In neonatal Wistar rats injected with streptozotocin (STZ) at birth (n0-STZ
model), a recognized model of β-cell regeneration, we investigated the capacity
of early treatment with glucagon-like peptide 1 (GLP-1) or exendin-4 to ... Cited by 171 - Related articles - BL Direct - All 5 versions
DDDLSD Reza, MRSADJ Drucker, DA … - 糖尿病学杂志, 2003 - journal.shouxi.net A reduction in ß-cell mass is an important causative factor in type 1 and type
2 diabetes. Glucagon-like peptide-1 (GLP-1) and the long-acting agonist exendin
4 (Ex-4) expand ß-cell mass by stimulating neogenesis and proliferation. ... Cited by 1 - Related articles - Cached
- ►endojournals.org H Hui, A Nourparvar, X Zhao, R Perfetti - Endocrinology, 2003 - Endocrine Soc The activation of the glucagon-like peptide-1 (GLP-1) receptor has been shown to
have an important role in the functional activity of islet ß-cells and in the
expansion of the islet cell mass. Constant remodeling of islet cell mass is ... Cited by 141 - Related articles - BL Direct - All 4 versions
J Buteau, S Foisy, CJ Rhodes, L Carpenter, TJ … - Diabetes, 2001 - Am Diabetes Assoc Glucagon-like peptide-1 (GLP-1), an insulinotropic and glucoincretin hormone, is
a potentially important therapeutic agent in the treatment of diabetes. We
previously provided evidence that GLP-1 induces pancreatic β-cell growth ... Cited by 138 - Related articles - BL Direct - All 4 versions
J Zhou, MA Pineyro, X Wang, ME Doyle, JM … - Journal of cellular physiology, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 63 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org DA Stoffers, BM Desai, DD DeLeon, RA … - Diabetes, 2003 - Am Diabetes Assoc Uteroplacental insufficiency resulting in fetal growth retardation is a common
complication of pregnancy and a significant cause of perinatal morbidity and
mortality. Epidemiological studies show an increased incidence of type 2 ... Cited by 88 - Related articles - BL Direct - All 4 versions
